V5med Lung AI

The V5med Lung AI is a Computer-Aided Detection (CAD) software designed to assist radiologists in identifying pulmonary nodules (4-30 mm) during chest CT scans in asymptomatic individuals. Utilizing a Deep Convolutional Neural Network (CNN) algorithm, this device was clinically validated to significantly improve nodule detection accuracy and reduce reading time, demonstrating superior performance compared to unaided reads.

V5med Inc. has received clearance for its V5med Lung AI, a Computer-Aided Detection (CAD) software. This software is designed to assist radiologists in the detection of pulmonary nodules, specifically those with a diameter of 4-30 mm, during CT examinations of the chest in asymptomatic populations. The determination indicates that the device is substantially equivalent to legally marketed devices, allowing it to be commercially available. It is intended to provide adjunctive information, alerting radiologists to regions of interest with suspected lung nodules that might otherwise be overlooked, and is suitable for use in a concurrent read mode alongside original CT images. The V5med Lung AI employs a Deep Convolutional Neural Network (CNN) based algorithm for automatic nodule detection. Non-clinical evaluations included comprehensive software testing, which verified the system's functionalities and measurement performance. A pivotal clinical reader study, involving sixteen board-certified radiologists and 340 chest CT scans, demonstrated the device's effectiveness. The study revealed a significant increase in the Area Under the Curve (AUC) for nodule detection and a notable 13% reduction in reading time when radiologists used V5med Lung AI, confirming its superior performance compared to unaided reads and its substantial equivalence to existing devices.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What are the specific sensitivity and specificity values of V5med Lung AI for different nodule sizes within the 4-30mm range?; How does the performance of V5med Lung AI compare to other commercially available CAD software in terms of false positive rates and clinician workflow integration?; Were there specific types of nodules (e.g., solid, subsolid, calcified) or anatomical locations where V5med Lung AI demonstrated particularly strong or weak performance?; What post-market surveillance or real-world evidence collection is planned to further assess the long-term impact of V5med Lung AI on diagnostic accuracy and patient outcomes?; Could the V5med Lung AI be adapted or further developed to aid in the characterization of nodules, not just detection, to differentiate benign from malignant findings?